AU2017326423B2 - High purity RNA compositions and methods for preparation thereof - Google Patents

High purity RNA compositions and methods for preparation thereof Download PDF

Info

Publication number
AU2017326423B2
AU2017326423B2 AU2017326423A AU2017326423A AU2017326423B2 AU 2017326423 B2 AU2017326423 B2 AU 2017326423B2 AU 2017326423 A AU2017326423 A AU 2017326423A AU 2017326423 A AU2017326423 A AU 2017326423A AU 2017326423 B2 AU2017326423 B2 AU 2017326423B2
Authority
AU
Australia
Prior art keywords
alpha
rna
equi
ppp
utp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017326423A
Other languages
English (en)
Other versions
AU2017326423A1 (en
Inventor
Gabor Butora
Stephen Hoge
William Issa
Edward J. MIRACCO
Jennifer Nelson
Amy E. Rabideau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ModernaTx Inc
Original Assignee
ModernaTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60043282&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2017326423(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ModernaTx Inc filed Critical ModernaTx Inc
Publication of AU2017326423A1 publication Critical patent/AU2017326423A1/en
Application granted granted Critical
Publication of AU2017326423B2 publication Critical patent/AU2017326423B2/en
Priority to AU2024200861A priority Critical patent/AU2024200861A1/en
Priority to AU2026204812A priority patent/AU2026204812A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
AU2017326423A 2016-09-14 2017-09-14 High purity RNA compositions and methods for preparation thereof Ceased AU2017326423B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2024200861A AU2024200861A1 (en) 2016-09-14 2024-02-09 High purity RNA compositions and methods for preparation thereof
AU2026204812A AU2026204812A1 (en) 2016-09-14 2026-06-23 High purity RNA compositions and methods for preparation thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662394711P 2016-09-14 2016-09-14
US62/394,711 2016-09-14
PCT/US2017/051674 WO2018053209A1 (en) 2016-09-14 2017-09-14 High purity rna compositions and methods for preparation thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024200861A Division AU2024200861A1 (en) 2016-09-14 2024-02-09 High purity RNA compositions and methods for preparation thereof

Publications (2)

Publication Number Publication Date
AU2017326423A1 AU2017326423A1 (en) 2019-03-28
AU2017326423B2 true AU2017326423B2 (en) 2023-11-09

Family

ID=60043282

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2017326423A Ceased AU2017326423B2 (en) 2016-09-14 2017-09-14 High purity RNA compositions and methods for preparation thereof
AU2024200861A Abandoned AU2024200861A1 (en) 2016-09-14 2024-02-09 High purity RNA compositions and methods for preparation thereof
AU2026204812A Pending AU2026204812A1 (en) 2016-09-14 2026-06-23 High purity RNA compositions and methods for preparation thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2024200861A Abandoned AU2024200861A1 (en) 2016-09-14 2024-02-09 High purity RNA compositions and methods for preparation thereof
AU2026204812A Pending AU2026204812A1 (en) 2016-09-14 2026-06-23 High purity RNA compositions and methods for preparation thereof

Country Status (11)

Country Link
US (5) US11202793B2 (enExample)
EP (2) EP3512944B1 (enExample)
JP (3) JP6983455B2 (enExample)
CN (2) CN109937253B (enExample)
AU (3) AU2017326423B2 (enExample)
CA (1) CA3036831A1 (enExample)
ES (1) ES2928475T3 (enExample)
MA (1) MA46240A (enExample)
MX (1) MX2019002904A (enExample)
SG (1) SG11201901941YA (enExample)
WO (1) WO2018053209A1 (enExample)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498588A (en) 1994-09-09 1996-03-12 The Standard Oil Company Surface modification and promotion of vanadium antimony oxide catalysts
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
SG11201803360UA (en) 2015-10-22 2018-05-30 Modernatx Inc Nucleic acid vaccines for varicella zoster virus (vzv)
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
MA45209A (fr) 2015-10-22 2019-04-17 Modernatx Inc Vaccins contre les maladies sexuellement transmissibles
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
DK3386484T3 (da) 2015-12-10 2022-07-04 Modernatx Inc Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
CN115837014A (zh) 2016-05-18 2023-03-24 摩登纳特斯有限公司 编码松弛素的多核苷酸
US12128113B2 (en) 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
SG11201901941YA (en) 2016-09-14 2019-04-29 Modernatx Inc High purity rna compositions and methods for preparation thereof
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
MA46766A (fr) 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
EP3551193A4 (en) 2016-12-08 2020-08-19 Modernatx, Inc. NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
EP3555289A1 (en) 2016-12-13 2019-10-23 ModernaTX, Inc. Rna affinity purification
MA47515A (fr) 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
WO2018170260A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
MA48047A (fr) 2017-04-05 2020-02-12 Modernatx Inc Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
WO2019036682A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. RNA VARIANTS POLYMERASE
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
CN112996854B (zh) 2018-09-19 2024-08-30 摩登纳特斯有限公司 高纯度peg脂质和其用途
US12151029B2 (en) 2018-09-19 2024-11-26 Modernatx, Inc. PEG lipids and uses thereof
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
CN113939282A (zh) 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
MX2021010075A (es) 2019-02-20 2021-12-10 Modernatx Inc Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales.
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
MX2021011031A (es) * 2019-03-11 2021-12-10 Modernatx Inc Proceso de transcripción in vitro en lotes alimentados.
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
EP4010481A4 (en) 2019-08-09 2023-09-20 Nutcracker Therapeutics, Inc. MICROFLUIDIC DEVICE AND METHODS OF USE
CN110812366B (zh) * 2019-11-18 2023-11-17 珠海丽凡达生物技术有限公司 一种可用于激素补充的mRNA药物及其制备方法
WO2021154763A1 (en) 2020-01-28 2021-08-05 Modernatx, Inc. Coronavirus rna vaccines
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
BR112022015565A2 (pt) 2020-02-07 2022-09-27 Modernatx Inc Vacinas de domínio de mrna para sars-cov-2
CN118490818A (zh) 2020-04-22 2024-08-16 生物技术欧洲股份公司 冠状病毒疫苗
WO2021222304A1 (en) 2020-04-27 2021-11-04 Modernatx, Inc. Sars-cov-2 rna vaccines
WO2021159130A2 (en) 2020-05-15 2021-08-12 Modernatx, Inc. Coronavirus rna vaccines and methods of use
WO2021231929A1 (en) * 2020-05-15 2021-11-18 Modernatx, Inc. Rna formulations for high volume distribution
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
US20230355743A1 (en) 2020-09-25 2023-11-09 Modernatx, Inc. Multi-proline-substituted coronavirus spike protein vaccines
CN116438298A (zh) * 2020-10-15 2023-07-14 翻译生物公司 信使rna的大规模合成
MX2023007574A (es) 2020-12-22 2023-09-29 CureVac SE "vacuna de arn contra variantes de sars-cov-2.
WO2022150717A1 (en) 2021-01-11 2022-07-14 Modernatx, Inc. Seasonal rna influenza virus vaccines
AU2022207495A1 (en) 2021-01-15 2023-08-03 Modernatx, Inc. Variant strain-based coronavirus vaccines
US20240100151A1 (en) 2021-01-15 2024-03-28 Moderna TX, Inc. Variant strain-based coronavirus vaccines
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
JP2024511346A (ja) 2021-03-15 2024-03-13 モデルナティエックス インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２ ｍｒｎａドメインワクチンの治療的使用
EP4326227A1 (en) 2021-04-23 2024-02-28 ModernaTX, Inc. Stabilized formulations
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
WO2022245888A1 (en) 2021-05-19 2022-11-24 Modernatx, Inc. Seasonal flu rna vaccines and methods of use
EP4347883A1 (en) * 2021-05-26 2024-04-10 eTheRNA immunotherapies NV Method to reduce double stranded rna by-product formation
EP4355875A1 (en) * 2021-06-14 2024-04-24 2seventy bio, Inc. Single stranded rna purification methods
WO2022266389A1 (en) 2021-06-17 2022-12-22 Modernatx, Inc. Alternative rna purification strategies
US20240352496A1 (en) * 2021-08-31 2024-10-24 Glaxosmithkline Biologicals Sa Ivt rna manufacturing process
KR20240090727A (ko) 2021-10-22 2024-06-21 세일 바이오메디슨스, 인크. Mrna 백신 조성물
WO2023092069A1 (en) 2021-11-18 2023-05-25 Modernatx, Inc. Sars-cov-2 mrna domain vaccines and methods of use
US20250002941A1 (en) 2021-11-23 2025-01-02 Sail Biomedicines, Inc. A bacteria-derived lipid composition and use thereof
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US20250360194A1 (en) 2021-12-08 2025-11-27 Modernatx, Inc. Herpes simplex virus mrna vaccines
WO2023112886A1 (ja) * 2021-12-16 2023-06-22 国立研究開発法人理化学研究所 １本鎖ｒｎａの製造方法
EP4452239A1 (en) 2021-12-20 2024-10-30 Sail Biomedicines, Inc. Compositions comprising mrna and lipid reconstructed plant messenger packs
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
EP4463545A1 (en) * 2022-01-14 2024-11-20 ModernaTX, Inc. In vitro transcription dna purification and recycling
WO2023196914A1 (en) 2022-04-08 2023-10-12 Modernatx, Inc. Influenza nucleic acid compositions and uses thereof
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024015890A1 (en) 2022-07-13 2024-01-18 Modernatx, Inc. Norovirus mrna vaccines
WO2024020194A1 (en) * 2022-07-22 2024-01-25 Modernatx, Inc. Compositions and methods for detecting dsrna
WO2024050483A1 (en) 2022-08-31 2024-03-07 Modernatx, Inc. Variant strain-based coronavirus vaccines and uses thereof
JP2025528589A (ja) * 2022-09-13 2025-08-28 スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド 環状ｒｎａのワンステップ合成法
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
EP4615424A1 (en) 2022-11-10 2025-09-17 Sail Biomedicines, Inc. Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
AU2024209872A1 (en) 2023-01-20 2025-09-04 Astrazeneca Ab Nucleic acid molecules
JP2026501855A (ja) 2023-01-20 2026-01-16 アストラゼネカ・アクチエボラーグ ワクチン
JP2026503676A (ja) 2023-01-27 2026-01-29 セイル バイオメディシンズ インコーポレイテッド 修飾脂質組成物およびその使用
JP2026503718A (ja) 2023-01-30 2026-01-29 モデルナティエックス インコーポレイテッド エプスタイン・バーウイルスｍＲＮＡワクチン
EP4676526A2 (en) 2023-03-10 2026-01-14 ModernaTX, Inc. Nucleic acid influenza vaccines and respiratory virus combination vaccines
WO2024206835A1 (en) 2023-03-30 2024-10-03 Modernatx, Inc. Circular mrna and production thereof
WO2024215721A1 (en) 2023-04-10 2024-10-17 Modernatx, Inc. Lyme disease vaccines
WO2024220712A2 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Vaccine compositions
CN116606867B (zh) * 2023-04-28 2024-01-26 北京启辰生生物科技有限公司 一种提高新冠全长S蛋白mRNA完整性的制备方法及用途
WO2024254552A1 (en) 2023-06-08 2024-12-12 Modernatx, Inc. Stabilized flavivirus vaccines
WO2024263826A1 (en) 2023-06-22 2024-12-26 Modernatx, Inc. Sars-cov-2 t cell vaccines
WO2025019352A2 (en) 2023-07-14 2025-01-23 Modernatx, Inc. Mers-cov mrna vaccines
EP4750907A1 (en) * 2023-07-26 2026-06-03 Kudo Biotechnology, Inc. Method of mrna manufacture
WO2025029700A1 (en) 2023-07-28 2025-02-06 Modernatx, Inc. Vlp enteroviral vaccines
WO2025034612A1 (en) 2023-08-04 2025-02-13 Modernatx, Inc. Varicella-zoster virus mrna vaccine
WO2025226656A1 (en) 2024-04-23 2025-10-30 Modernatx, Inc. Hepatitis b virus mrna vaccines
WO2025250938A2 (en) 2024-05-31 2025-12-04 Modernatx, Inc. Respiratory syncytial virus and metapneumovirus vaccines
WO2026080379A1 (en) 2024-10-07 2026-04-16 Modernatx, Inc. Lyme disease mrna vaccines
WO2026128724A1 (en) 2024-12-11 2026-06-18 Modernatx, Inc. Stabilized flavivirus vaccines
WO2026143086A1 (en) 2024-12-24 2026-07-02 Modernatx, Inc. Shuffled polypeptide vaccines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013102203A1 (en) * 2011-12-30 2013-07-04 Cellscript, Inc. MAKING AND USING IN VITRO-SYNTHESIZED ssRNA FOR INTRODUCING INTO MAMMALIAN CELLS TO INDUCE A BIOLOGICAL OR BIOCHEMICAL EFFECT
WO2015188933A1 (en) * 2014-06-10 2015-12-17 Curevac Ag Methods and means for enhancing rna production

Family Cites Families (241)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100024A (en) 1991-02-08 2000-08-08 Promega Corporation Methods and compositions for nucleic acid detection by target extension and probe amplification
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
US5256555A (en) * 1991-12-20 1993-10-26 Ambion, Inc. Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
WO1995008626A1 (en) 1993-09-20 1995-03-30 The Regents Of The University Of Colorado Strategy for the production of rna from immobilized templates
US6096503A (en) 1993-11-12 2000-08-01 The Scripps Research Institute Method for simultaneous identification of differentially expresses mRNAs and measurement of relative concentrations
FR2733762B1 (fr) 1995-05-02 1997-08-01 Genset Sa Methode de couplage specifique de la coiffe de l'extremite 5' d'un fragment d'arnm et preparation d'arnm et d'adnc complet
US6251665B1 (en) 1997-02-07 2001-06-26 Cem Cezayirli Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom
US6528262B1 (en) 1999-10-06 2003-03-04 Quark Biotech, Inc. Method for enrichment of natural antisense messenger RNA
US20030165849A1 (en) 2000-11-28 2003-09-04 Biliang Zhang Methods and reagents for introducing a sulfhydryl group into the 5'-terminus of RNA
WO2002048310A2 (en) * 2000-12-15 2002-06-20 Genetics Institute, Llc Methods and compositions for diagnosing and treating rheumatoid arthritis
US8426194B2 (en) 2003-01-21 2013-04-23 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating VEGF expression
GB0316089D0 (en) 2003-07-09 2003-08-13 Xo Bioscience Ltd Differentiation method
US20140142290A1 (en) 2003-08-01 2014-05-22 Life Technologies Corporation Compositions and methods for preparing short rna molecules and other nucleicacids
US20050054847A1 (en) * 2003-08-01 2005-03-10 Invitrogen Corporation Compositions and methods for preparing short RNA molecules and other nucleic acids
US20050287539A1 (en) * 2004-06-29 2005-12-29 Emmanuel Labourier Methods and compositions for preparing capped RNA
WO2007014363A2 (en) 2005-07-27 2007-02-01 Genentech, Inc. Vectors for inducible expression of hairpin rna and use thereof
US9012219B2 (en) * 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
EP2010659B1 (en) 2006-04-14 2014-06-18 CellScript, Inc. Kits and methods for generating 5' capped RNA
WO2008140615A2 (en) 2006-12-21 2008-11-20 Novozymes, Inc. Modified messenger rna stabilizing sequences for expressing genes in bacterial cells
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
EP2451475A2 (en) 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
ES2769129T3 (es) 2009-12-07 2020-06-24 Univ Pennsylvania Preparaciones de ARN que comprenden ARN modificado purificado para reprogramar células
WO2011149733A2 (en) 2010-05-24 2011-12-01 Merck Sharp & Dohme Corp. Novel amino alcohol cationic lipids for oligonucleotide delivery
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP2013539969A (ja) * 2010-09-21 2013-10-31 リボックス・ゲーエムベーハー カリシウイルスのｒｎａポリメラーゼによる、マイクロ波によって駆動されるｒｎａ重合
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
AU2011329753B2 (en) 2010-11-19 2015-07-23 The Regents Of The University Of Michigan ncRNA and uses thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
CN103687957A (zh) 2011-05-17 2014-03-26 现代治疗公司 工程化核酸及其用于非人类脊椎动物的方法
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3384938A1 (en) 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013130161A1 (en) 2011-12-14 2013-09-06 modeRNA Therapeutics Methods of responding to a biothreat
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
AU2012358384A1 (en) 2011-12-21 2014-07-31 Moderna Therapeutics, Inc. Methods of increasing the viability or longevity of an organ or organ explant
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9512456B2 (en) 2012-08-14 2016-12-06 Modernatx, Inc. Enzymes and polymerases for the synthesis of RNA
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
WO2014093574A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified polynucleotides for altering cell phenotype
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
EA201591229A1 (ru) 2013-03-14 2016-01-29 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
EA201591283A1 (ru) 2013-03-14 2016-02-29 Шир Хьюман Дженетик Терапис, Инк. Количественная оценка эффективности кэп матричной рнк
WO2014160243A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP4279610A3 (en) 2013-03-15 2024-01-03 ModernaTX, Inc. Ribonucleic acid purification
EP2971033B8 (en) 2013-03-15 2019-07-10 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
US20160032273A1 (en) 2013-03-15 2016-02-04 Moderna Therapeutics, Inc. Characterization of mrna molecules
WO2014144711A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
PL2970948T3 (pl) 2013-03-15 2019-06-28 Glaxosmithkline Biologicals Sa Sposoby oczyszczania rna
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
PL3019619T3 (pl) 2013-07-11 2022-01-10 Modernatx, Inc. Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
US20160243221A1 (en) 2013-10-18 2016-08-25 Moderna Therapeutics, Inc. Compositions and methods for tolerizing cellular systems
US20170173128A1 (en) 2013-12-06 2017-06-22 Moderna TX, Inc. Targeted adaptive vaccines
AU2015231031A1 (en) 2014-03-20 2016-09-22 The Board Of Regents Of The University Of Texas System T7 RNA polymerase variants with expanded substrate range and enhanced transcriptional yield
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
US10286086B2 (en) 2014-06-19 2019-05-14 Modernatx, Inc. Alternative nucleic acid molecules and uses thereof
WO2016011226A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20170202979A1 (en) 2014-07-17 2017-07-20 Modernatx, Inc. Terminal modifications of polynucleotides
WO2016118724A1 (en) 2015-01-21 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
WO2016164762A1 (en) 2015-04-08 2016-10-13 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
EP3289077B1 (en) 2015-04-30 2020-04-15 CureVac AG Method for in vitro transcription using an immobilized restriction enzyme
WO2016201377A1 (en) 2015-06-10 2016-12-15 Moderna Therapeutics, Inc. Targeted adaptive vaccines
WO2017011773A2 (en) 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
WO2017015457A1 (en) 2015-07-21 2017-01-26 Modernatx, Inc. Ebola vaccine
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
US20190008887A1 (en) 2015-07-30 2019-01-10 ModernaTX Inc. Multimeric mrna
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
US20180237849A1 (en) 2015-08-17 2018-08-23 Modernatx, Inc. Rna mapping/fingerprinting
HRP20220156T1 (hr) 2015-09-17 2022-04-15 Modernatx, Inc. Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
EP3359670B2 (en) 2015-10-05 2024-02-14 ModernaTX, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
MA46023A (fr) 2015-10-22 2019-07-03 Modernatx Inc Vaccin contre le virus de la grippe à large spectre
SG11201803360UA (en) 2015-10-22 2018-05-30 Modernatx Inc Nucleic acid vaccines for varicella zoster virus (vzv)
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
US20180271970A1 (en) 2015-10-22 2018-09-27 Modernatx, Inc. Respiratory syncytial virus vaccine
MA45209A (fr) 2015-10-22 2019-04-17 Modernatx Inc Vaccins contre les maladies sexuellement transmissibles
PE20181531A1 (es) 2015-10-22 2018-09-26 Modernatx Inc Vacuna del virus herpes simple
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
DK3386484T3 (da) 2015-12-10 2022-07-04 Modernatx Inc Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
WO2017106799A1 (en) 2015-12-17 2017-06-22 Modernatx, Inc. POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE
RS63051B1 (sr) 2015-12-22 2022-04-29 Modernatx Inc Jedinjenja i kompozicije za intracelularnu isporuku agenasa
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
EP3402881B1 (en) 2016-01-13 2021-04-28 New England Biolabs, Inc. Thermostable variants of t7 rna polymerase
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
EP3458106A4 (en) 2016-05-18 2020-03-18 Modernatx, Inc. POLYNUCLEOTIDS FOR CODING LIPOPROTEIN LIPASE FOR TREATING HYPERLIPIDEMIA
US11001861B2 (en) 2016-05-18 2021-05-11 Modernatx, Inc. Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
US20190382774A1 (en) 2016-05-18 2019-12-19 Modernatx, Inc. Polyribonucleotides containing reduced uracil content and uses thereof
PL3458083T3 (pl) 2016-05-18 2023-03-13 Modernatx, Inc. Polinukleotydy kodujące interleukinę-12 (il12) i ich zastosowania
US11801227B2 (en) 2016-05-18 2023-10-31 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
US12128113B2 (en) 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
AU2017268396B2 (en) 2016-05-18 2023-05-18 Modernatx, Inc. Polynucleotides encoding citrin for the treatment of citrullinemia type 2
WO2017201332A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding acyl-coa dehydrogenase, very long-chain for the treatment of very long-chain acyl-coa dehydrogenase deficiency
CA3024509A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
JP2019519601A (ja) 2016-05-18 2019-07-11 モダーナティエックス・インコーポレイテッドＭｏｄｅｒｎａＴＸ， Ｉｎｃ． 急性間欠性ポルフィリン症の治療のためのポルホビリノゲン脱アミノ酵素をコードするポリヌクレオチド
JP7114485B2 (ja) 2016-05-18 2022-08-08 モデルナティエックス インコーポレイテッド ファブリー病の治療のためのα－ガラクトシダーゼＡをコードするポリヌクレオチド
CN115837014A (zh) 2016-05-18 2023-03-24 摩登纳特斯有限公司 编码松弛素的多核苷酸
EP3468537A1 (en) 2016-06-14 2019-04-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
CN106244608B (zh) 2016-08-08 2019-10-25 中国科学技术大学 诱导的t7 rna聚合酶
SG11201901941YA (en) 2016-09-14 2019-04-29 Modernatx Inc High purity rna compositions and methods for preparation thereof
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
CA3042015A1 (en) 2016-10-26 2018-05-03 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
MA46643A (fr) 2016-10-26 2019-09-04 Modernatx Inc Méthodes et compositions pour le mappage d'arn
EP3538067A1 (en) 2016-11-08 2019-09-18 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
MA46766A (fr) 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
EP3551193A4 (en) 2016-12-08 2020-08-19 Modernatx, Inc. NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
EP3555289A1 (en) 2016-12-13 2019-10-23 ModernaTX, Inc. Rna affinity purification
US20180243225A1 (en) 2017-01-25 2018-08-30 Modernatx, Inc. Ebola/marburg vaccines
WO2018144778A1 (en) 2017-02-01 2018-08-09 Modernatx, Inc. Polynucleotide secondary structure
CA3052255A1 (en) 2017-02-01 2018-08-09 Modernatx, Inc. Rna cancer vaccines
MX2019009070A (es) 2017-02-01 2019-10-30 Modernatx Inc Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
MA47515A (fr) 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
US20200368162A1 (en) 2017-02-24 2020-11-26 Modernatx, Inc. Nucleic Acid-Based Therapy of Muscular Dystrophies
WO2018170260A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
JP7332478B2 (ja) 2017-03-15 2023-08-23 モデルナティエックス インコーポレイテッド 脂質ナノ粒子製剤
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
RS63953B1 (sr) 2017-03-15 2023-02-28 Modernatx Inc Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
US20200038499A1 (en) 2017-03-22 2020-02-06 Modernatx, Inc. Rna bacterial vaccines
MA48047A (fr) 2017-04-05 2020-02-12 Modernatx Inc Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
MA49463A (fr) 2017-04-26 2021-05-05 Modernatx Inc Vaccin contre le virus de l'herpès simplex
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
WO2018232355A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna antibodies
KR102773542B1 (ko) 2017-06-30 2025-02-25 코덱시스, 인코포레이티드 T7 rna 폴리머라제 변이체
EP3655040A1 (en) 2017-07-21 2020-05-27 Modernatx, Inc. Modified mrna encoding a propionyl-coa carboxylase and uses thereof
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
WO2019036670A2 (en) 2017-08-18 2019-02-21 Modernatx, Inc. EFFECTIVE MRNA VACCINES
WO2019036682A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. RNA VARIANTS POLYMERASE
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
MA50522B1 (fr) 2017-10-31 2022-09-30 Astrazeneca Ab 151 85 Soedertaelje Nanoparticules lipidiques pour l'administration d'un arn modifié codant pour un polypeptide vegf-a
US20190192646A1 (en) 2017-11-03 2019-06-27 Modernatx, Inc. Salmonella vaccines
MA50813A (fr) 2017-11-21 2020-09-30 Modernatx Inc Vaccins contre le virus d'epstein-barr
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
US20210268086A1 (en) 2018-06-27 2021-09-02 Modernatx, Inc. Personalized cancer vaccine epitope selection
US20220054653A1 (en) 2018-09-13 2022-02-24 Modernatx, Inc. Modified mrna for the treatment of progressive familial intrahepatic cholestasis disorders
US12151029B2 (en) 2018-09-19 2024-11-26 Modernatx, Inc. PEG lipids and uses thereof
EP3853202A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
CN112996854B (zh) 2018-09-19 2024-08-30 摩登纳特斯有限公司 高纯度peg脂质和其用途
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
MA54192A (fr) 2018-11-07 2021-09-15 Modernatx Inc Vaccins à arn contre le cancer
CN113939282A (zh) 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
MX2021010075A (es) 2019-02-20 2021-12-10 Modernatx Inc Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales.
MX2021011031A (es) 2019-03-11 2021-12-10 Modernatx Inc Proceso de transcripción in vitro en lotes alimentados.
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
JP2022535006A (ja) 2019-05-31 2022-08-04 モデルナティエックス インコーポレイテッド 増殖ｔ細胞アッセイ
US20220348900A1 (en) 2019-08-14 2022-11-03 Modernatx, Inc. Processes for purifying downstream products of in vitro transcription
EP4028030A4 (en) 2019-09-11 2023-09-27 ModernaTX, Inc. VACCINE AGAINST HUMAN CYTOMEGALOVIRUS
JP2022548957A (ja) 2019-09-19 2022-11-22 モデルナティエックス インコーポレイテッド キャップガイド及びｒｎａマッピングのためのその使用方法
EP4031524A1 (en) 2019-09-19 2022-07-27 ModernaTX, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
EP4088281A4 (en) 2020-01-10 2024-02-21 ModernaTX, Inc. VARIOUS AUTOCECODER FOR GENERATING BIOLOGICAL SEQUENCE
US20210228707A1 (en) 2020-01-28 2021-07-29 Modernatx, Inc. Coronavirus rna vaccines
KR20220133911A (ko) 2020-01-30 2022-10-05 모더나티엑스, 인크. 호흡기 바이러스 면역화 조성물
US20230285297A1 (en) 2020-01-31 2023-09-14 Modernatx, Inc. Methods of preparing lipid nanoparticles
BR112022015565A2 (pt) 2020-02-07 2022-09-27 Modernatx Inc Vacinas de domínio de mrna para sars-cov-2
WO2021211343A1 (en) 2020-04-13 2021-10-21 Modernatx, Inc. Zika virus mrna vaccines
WO2021222304A1 (en) 2020-04-27 2021-11-04 Modernatx, Inc. Sars-cov-2 rna vaccines
WO2021231929A1 (en) 2020-05-15 2021-11-18 Modernatx, Inc. Rna formulations for high volume distribution
WO2021159130A2 (en) 2020-05-15 2021-08-12 Modernatx, Inc. Coronavirus rna vaccines and methods of use
EP4153238A4 (en) 2020-05-21 2024-12-18 ModernaTX, Inc. METHYLENE BLUE STABILIZED MRNA COMPOSITIONS
US20230287437A1 (en) 2020-06-05 2023-09-14 Modernatx, Inc. Bacterial strains for dna production
WO2022032154A2 (en) 2020-08-06 2022-02-10 Modernatx, Inc. Compositions for the delivery of payload molecules to airway epithelium
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
US20230355743A1 (en) 2020-09-25 2023-11-09 Modernatx, Inc. Multi-proline-substituted coronavirus spike protein vaccines
WO2022150717A1 (en) 2021-01-11 2022-07-14 Modernatx, Inc. Seasonal rna influenza virus vaccines
AU2022207495A1 (en) 2021-01-15 2023-08-03 Modernatx, Inc. Variant strain-based coronavirus vaccines
US20240100151A1 (en) 2021-01-15 2024-03-28 Moderna TX, Inc. Variant strain-based coronavirus vaccines
EP4301405A4 (en) 2021-03-05 2025-01-29 ModernaTX, Inc. ENTEROVIRAL VACCINES WITH VIRUS-LIKE PARTICLES (VLP)
JP2024511346A (ja) 2021-03-15 2024-03-13 モデルナティエックス インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２ ｍｒｎａドメインワクチンの治療的使用
US20240181030A1 (en) 2021-03-26 2024-06-06 Modernatx, Inc. Pertussis vaccine
WO2022212442A1 (en) 2021-03-31 2022-10-06 Modernatx, Inc. Synthesis of trinucleotide and tetranucleotide caps for mrna production
WO2022212191A1 (en) 2021-04-01 2022-10-06 Modernatx, Inc. Mucosal expression of antibody structures and isotypes by mrna
JP2024512780A (ja) 2021-04-01 2024-03-19 モデルナティエックス インコーポレイテッド 多価ｒｎａ組成物中のｒｎａ種の識別及び比率決定のための方法
JP2024514183A (ja) 2021-04-13 2024-03-28 モデルナティエックス インコーポレイテッド エプスタイン－バーウイルスｍＲＮＡワクチン
WO2022221336A1 (en) 2021-04-13 2022-10-20 Modernatx, Inc. Respiratory syncytial virus mrna vaccines
WO2022221335A1 (en) 2021-04-13 2022-10-20 Modernatx, Inc. Respiratory virus combination vaccines
EP4322994A1 (en) 2021-04-14 2024-02-21 ModernaTX, Inc. Influenza-coronavirus combination vaccines
WO2022226318A1 (en) 2021-04-23 2022-10-27 Modernatx, Inc. Isoquinoline-stabilized lipid nanoparticle formulations
EP4326227A1 (en) 2021-04-23 2024-02-28 ModernaTX, Inc. Stabilized formulations
US20240226028A1 (en) 2021-04-29 2024-07-11 Modernatx, Inc. Lyophilization methods for preparing lipid formulated therapeutics
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
WO2022245888A1 (en) 2021-05-19 2022-11-24 Modernatx, Inc. Seasonal flu rna vaccines and methods of use
WO2022266010A1 (en) 2021-06-14 2022-12-22 Modernatx, Inc. Mrna vaccines encoding flexible coronavirus spike proteins
WO2022266012A1 (en) 2021-06-14 2022-12-22 Modernatx, Inc. Coronavirus glycosylation variant vaccines
WO2022266389A1 (en) 2021-06-17 2022-12-22 Modernatx, Inc. Alternative rna purification strategies
EP4366768A4 (en) 2021-07-09 2025-05-21 ModernaTX, Inc. Pan-human coronavirus vaccines
US20240358819A1 (en) 2021-07-09 2024-10-31 Modernatx, Inc. Pan-human coronavirus domain vaccines
WO2023283642A2 (en) 2021-07-09 2023-01-12 Modernatx, Inc. Pan-human coronavirus concatemeric vaccines
EP4381059A1 (en) 2021-08-02 2024-06-12 ModernaTX, Inc. Extraction-less reverse phase (rp) chromatography of mrna encapsulated in lipid nanoparticles for mrna purity assessment
US20250281418A1 (en) 2021-08-11 2025-09-11 Modernatx, Inc. Lipid nanoparticle formulations and methods of synthesis thereof
WO2023019181A1 (en) 2021-08-11 2023-02-16 Modernatx, Inc. Sars-cov-2 lipid nanoparticle vaccine formulations
WO2023018923A1 (en) 2021-08-13 2023-02-16 Modernatx, Inc. Multicolumn chromatography mrna purification
WO2023056401A1 (en) 2021-10-01 2023-04-06 Modernatx, Inc. Rna formulations for high volume distribution, and methods of using the same for treating a disease or condition caused by or associated with human cytomegalovirus
WO2023069900A1 (en) 2021-10-18 2023-04-27 Modernatx, Inc. Custom bacterial strain for recombinant protein production
WO2023069895A1 (en) 2021-10-18 2023-04-27 Modernatx, Inc. Markerless dna production
EP4419082A1 (en) 2021-10-20 2024-08-28 ModernaTX, Inc. Drug product surrogate solutions
EP4426853A1 (en) 2021-11-01 2024-09-11 ModernaTX, Inc. Mass spectrometry of mrna
US20240425902A1 (en) 2021-11-05 2024-12-26 Moderna TX, Inc. Methods of purifying dna for gene synthesis
WO2023092069A1 (en) 2021-11-18 2023-05-25 Modernatx, Inc. Sars-cov-2 mrna domain vaccines and methods of use
US20250360194A1 (en) 2021-12-08 2025-11-27 Modernatx, Inc. Herpes simplex virus mrna vaccines
JP2025500257A (ja) 2021-12-15 2025-01-09 モデルナティエックス インコーポレイテッド 脂質ナノ粒子の封入効率の決定
US20250084397A1 (en) 2022-01-04 2025-03-13 Modernatx, Inc. Methods of purifying dna for gene synthesis
EP4463545A1 (en) 2022-01-14 2024-11-20 ModernaTX, Inc. In vitro transcription dna purification and recycling
JP2025506416A (ja) 2022-02-03 2025-03-11 モデルナティエックス インコーポレイテッド ｍＲＮＡ精製のための連続的沈殿
TW202345863A (zh) 2022-02-09 2023-12-01 美商現代公司 黏膜投與方法及調配物
WO2023196914A1 (en) 2022-04-08 2023-10-12 Modernatx, Inc. Influenza nucleic acid compositions and uses thereof
WO2023201204A1 (en) 2022-04-11 2023-10-19 Modernatx, Inc. Detection of mrna purity in a mixture
EP4508201A1 (en) 2022-04-14 2025-02-19 ModernaTX, Inc. Rna polymerase variants
WO2023201296A1 (en) 2022-04-15 2023-10-19 Modernatx, Inc. Ribosomal engagement potency assay
WO2023212696A1 (en) 2022-04-29 2023-11-02 Modernatx, Inc. Lyophilized human cytomegalovirus vaccines
EP4525830A1 (en) 2022-05-17 2025-03-26 ModernaTX, Inc. Preparation of highly concentrated mrna
WO2023250119A1 (en) 2022-06-24 2023-12-28 Modernatx, Inc. Methods of producing rna
US20250388963A1 (en) 2022-07-06 2025-12-25 Modernatx, Inc. Primer design for cell-free dna production
WO2024015890A1 (en) 2022-07-13 2024-01-18 Modernatx, Inc. Norovirus mrna vaccines
WO2024026005A1 (en) 2022-07-28 2024-02-01 Modernatx, Inc. Methods of rna purification
WO2024030369A1 (en) 2022-08-01 2024-02-08 Modernatx, Inc. Extraction-less reverse phase (rp) chromatography for mrna purity assessment
WO2024050483A1 (en) 2022-08-31 2024-03-07 Modernatx, Inc. Variant strain-based coronavirus vaccines and uses thereof
US20260176618A1 (en) 2022-11-03 2026-06-25 Modernatx, Inc. Chemical stability of mrna
US20260199239A1 (en) 2022-12-08 2026-07-16 Modernatx, Inc. Ionizable lipids with malonate tails
EP4648793A1 (en) 2023-01-11 2025-11-19 ModernaTX, Inc. Personalized cancer vaccines
JP2026503718A (ja) 2023-01-30 2026-01-29 モデルナティエックス インコーポレイテッド エプスタイン・バーウイルスｍＲＮＡワクチン

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013102203A1 (en) * 2011-12-30 2013-07-04 Cellscript, Inc. MAKING AND USING IN VITRO-SYNTHESIZED ssRNA FOR INTRODUCING INTO MAMMALIAN CELLS TO INDUCE A BIOLOGICAL OR BIOCHEMICAL EFFECT
WO2015188933A1 (en) * 2014-06-10 2015-12-17 Curevac Ag Methods and means for enhancing rna production

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Hartmann et al., Handbook of RNA Biochemistry, Second Edition, "Part I Rna Synthesis and Detection." 2014. p 1-27. *
KARIKÓ, K. et al., "Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA", 2011. NUCLEIC ACIDS RESEARCH, Vol.39, No.21, pages e142-1. *
NEDIALKOV, Y.A. et al., "NTP-driven Translocation by Human RNA Polymerase II", 2003. JBC, Vol.278, No.20, pages 18303-18312. *
THESS, A. et al., "Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals", 2015. MOLECULAR THERAPY, Vol.23, No.9, pages 1456-1464. *

Also Published As

Publication number Publication date
US12246029B2 (en) 2025-03-11
CN116837052A (zh) 2023-10-03
CA3036831A1 (en) 2018-03-22
JP2022000458A (ja) 2022-01-04
US20180363019A1 (en) 2018-12-20
AU2026204812A1 (en) 2026-07-09
EP4166666A1 (en) 2023-04-19
SG11201901941YA (en) 2019-04-29
CN109937253A (zh) 2019-06-25
CN109937253B (zh) 2023-06-30
US12233084B2 (en) 2025-02-25
MA46240A (fr) 2019-07-24
US10653712B2 (en) 2020-05-19
US20220096521A1 (en) 2022-03-31
US20220096522A1 (en) 2022-03-31
JP2019533476A (ja) 2019-11-21
AU2024200861A1 (en) 2024-02-29
EP3512944A1 (en) 2019-07-24
WO2018053209A1 (en) 2018-03-22
US11202793B2 (en) 2021-12-21
MX2019002904A (es) 2019-09-26
JP7566710B2 (ja) 2024-10-15
AU2017326423A1 (en) 2019-03-28
JP6983455B2 (ja) 2021-12-17
JP2025032068A (ja) 2025-03-11
ES2928475T3 (es) 2022-11-18
EP3512944B1 (en) 2022-07-06
US20250275999A1 (en) 2025-09-04
US20190247417A1 (en) 2019-08-15

Similar Documents

Publication Publication Date Title
US12233084B2 (en) High purity RNA compositions and methods for preparation thereof
US20240408191A1 (en) Nucleic acid vaccines
US20240209068A1 (en) Mucosal expression of antibody structures and isotypes by mrna
US20180273977A1 (en) Multimeric mrna
JP2023164537A (ja) Ｒｎａ癌ワクチン
JP2022546046A (ja) 修飾された環状ｒｎａ及びその使用法
TW201729838A (zh) 用於水痘帶狀疱疹病毒 (vzv)之核酸疫苗
BR112019015797A2 (pt) Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação
CA3173429A1 (en) Compositions and methods for the prevention and/or treatment of covid-19
US20250127870A1 (en) mRNA Vaccines Against Hantavirus
TW202345870A (zh) 具有延長半衰期之信使核糖核酸
WO2023050003A1 (en) Compositions and methods for the prevention and/or treatment of covid-19
HK40011289B (en) High purity rna compositions and methods for preparation thereof
HK40011289A (en) High purity rna compositions and methods for preparation thereof
KR102850225B1 (ko) 사스-코로나바이러스 2 감염증에 대한 rna 백신
HK40072892B (en) Nucleic acid vaccines
WO2024073848A1 (en) Compositions and methods for the prevention and/or treatment of covid-19
HK40072892A (en) Nucleic acid vaccines
CA3128078A1 (en) Compositions and methods for the prevention and/or treatment of covid-19

Legal Events

Date Code Title Description
CB Opposition filed

Opponent name: SEQIRUS INC.

ON Decision of a delegate or deputy of the commissioner of patents (result of patent office hearing)

Free format text: (2025) APO 21: DECISION: THE OPPOSITION IS SUCCESSFUL ON THE GROUNDS OF INVENTIVE STEP, CLEAR ENOUGH AND COMPLETE ENOUGH DISCLOSURE AND SUPPORT WITH REGARD TO CLAIMS 1-8 AND 11-20 AND FAILS ON THE GROUNDS OF CLARITY, UTILITY AND NOVELTY. I ALLOW THE APPLICANT TWO (2) MONTHS FROM THE DATE OF THIS DECISION TO FILE AMENDMENTS TO OVERCOME THE DEFICIENCIES IDENTIFIED IN THIS DECISION. I AWARD COSTS ACCORDING TO SCHEDULE 8 AGAINST THE APPLICANT, MODERNA TX, INC.

Opponent name: SEQIRUS INC.

Effective date: 20250704

MK16 Application refused